We’re revolutionizing medicine through our leadership in cellular technology.

Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cell therapy market. Founded on the belief that immunotherapy made from a patient’s own cells will transform disease treatment, Dendreon has worked tirelessly to make the fight against cancer personal.

Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy to harness the innate benefits of personalized cellular treatment made from a patient’s own immune cells.

Since its FDA-approval in 2010, nearly 40,000 men have been prescribed PROVENGE. Now Dendreon is helping to advance other cell therapies from clinic to market by leveraging the extensive experience of developing and commercializing PROVENGE.

Dendreon paved the way as the first FDA-approved cell therapy made from a patient’s own immune cells. Prior to the development of PROVENGE, there was no roadmap for how to establish and monitor critical process parameters, or the potency and stability of cellular therapeutics. Our work established such processes. Building on our achievements, we are now working with partners to provide the end-to-end manufacturing services and regulatory expertise needed to commercialize new treatments. Our hope is that by pushing research forward, we may change the lives of patients and their families.

Improving the lives of patients through innovative science and cellular therapies.
At Dendreon, we have a singular purpose: improving the lives of patients through innovative science and cellular therapies.

We enable the future of complex cell therapies through research, development, and strategic partnerships. By leveraging innovative science that delivers unique therapies, our work helps change lives.

Our patients are at the heart of what we do daily. We delivered the first autologous cell therapy to the market over a decade ago, and continue to drive the future of cell therapy to serve more patients and their families.